Recent Company News

• 09:29 PM ET Jul 02, 2026
  

  StreetAccount Sector Summary - China Healthcare June Recap

• 07:41 PM ET Jul 01, 2026
  

  UK Medicines and Healthcare products Regulatory Agency accepts Eisai's marketing authorization application for dayvigo for treatment of insomnia (¥4109.0000, 0)

• 02:08 AM ET Jun 30, 2026
  

  BioArctic announces partner Eisai will present new clinical and real-world evidence on lecanemab (Leqembi) at the Alzheimer's Association International Conference (AAIC) in London, July 12-15 (SEK 324.00, 0.00)

• 11:39 AM ET Jun 29, 2026
  

  China announces preliminary results of 2026 NRDL adjustment, 557 passed for basic medical insurance, 54 passed for commercial insurance list

• 07:38 AM ET Jun 29, 2026
  

  Eisai to present latest findings from Alzheimer's disease research at AAIC 2026 (¥4145.0000, 0)

• 07:42 PM ET Jun 25, 2026
  

  MHRA accepts Eisai's marketing application for taletrectinib for treatment of NSCLC (¥3949.0000, 0)

• 08:37 PM ET Jun 17, 2026
  

  NICE recommends Shanghai Henlius Biotech's Hetronifly with carboplatin and etoposide for untreated ES-SCLC (HK$59.55, 0.00)

• 09:44 AM ET Jun 15, 2026
  

  StreetAccount Summary - Private company transactions for the week ended 13-Jun

• 11:49 PM ET Jun 10, 2026
  

  StreetAccount Summary: Asian stocks reaching new 52-week highs/lows (154 total)

• 11:19 PM ET Jun 10, 2026
  

  StreetAccount Summary: Japan Stocks reaching new 52-week highs/lows (62 total)